Cancer Long Survivors Artificial Intelligence Follow Up

The number of cancer survivors has increased in recent years due to advances in diagnoses and treatment. Ensuring post-treatment quality of life of survivors remains a challenge. The EU-funded CLARIFY project will identify the risk factors for deterioration in a patient at the end of oncological treatment. Specifically, it will collect data about survivors from breast, lung and lymphoma cancer (the most prevalent types) from hospitals in Spain. Using big data and artificial intelligence techniques, it will integrate all data with relevant publicly available biomedical information, as well as information from wearable devices used after the treatment. The data will be analysed to predict patient-specific risk of developing secondary effects and toxicities from their cancer treatments.

Duration:  2020 – 2022 (36 months)

Funding source (Code): H2020 [RIA] (875160)

Participant entities: Servicio Madrileño de Salud, Universidad Politécnica de Madrid, Technische Informationsbibliothek (TIB), HOLOS S.A, National University of Ireland Galway, University College London, University College Dublin (NUI), Accenture, Grupo Oncológico para el Tratamiento y Estudio de los Linfomas, Stelar Security Technology Law Research, Grupo español de Investigación en Cancer de Pulmón, Kronohealth S.L.

Official webpage:  https://www.clarify2020.eu/

CORDIS webpage: https://cordis.europa.eu/project/id/875160/es

Laboratory/internal web: http://medal.ctb.upm.es/projects/CLARIFY/

Responsible: Ernestina Menasalvas Ruiz